FDA’s Woodcock Cautions Against Trying To “Legislate A New Generation Of Biomarkers”
This article was originally published in RPM Report
Executive Summary
New approaches to biomarker qualification are big part of industry’s agenda for “21st Century Cures,” but CDER Director Janet Woodcock remains concerned about efforts to legislate ahead of the science.